ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress
June 05, 2024Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) -
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)
January 12, 2023HighTide Therapeutics Inc. announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). -
HighTide Therapeutics Receives Fast Track Designation for HTD1801
September 29, 2018HighTide Therapeutics announced the FDA has granted Fast Track Designation to its investigational new drug, HTD1801, for the treatment of patients with primary sclerosing cholangitis (PSC).
Pharma Sources Insight January 2025
